SGMT

Sagimet Biosciences Inc. Class A · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website agimet.com
Employees(FY) 9
ISIN US7867001049

Performance

-23.91%

-16.45%

+60.28%

-2.16%

-16.61%

YTD

+50.17%

Profile

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Advanced Technical Analysis

Technical Analysis of SGMT 2024-11-20

The stock indicators reflect a mixed sentiment, with the Moving Average Score at 30 indicating a bearish outlook, while the Oscillators Score of 53 suggests a neutral stance, and the overall Technical Score of 41 reinforces a bearish sentiment. This combination implies caution, as the prevailing indicators do not signal strong bullish momentum.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of SGMT

Stock Rank

Recent News & Updates

2024-11-17 19:00
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting 2024(Globenewswire)
2024-11-13 19:00
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates(Globenewswire)
2024-11-11 17:30
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne(Prnewswire)
2024-11-06 18:30
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference(Globenewswire)
2024-10-28 19:00
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024(Globenewswire)
2024-10-15 19:00
Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting 2024(Globenewswire)
2024-10-10 19:00
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology(Globenewswire)
2024-10-01 00:05
Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-09-30 19:00
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH(Globenewswire)
2024-09-11 19:30
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit(Globenewswire)
2024-09-03 20:00
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences(Globenewswire)
2024-08-13 20:00
Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates(Globenewswire)
2024-07-31 20:00
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors(Globenewswire)
2024-06-09 20:00
Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat(Globenewswire)
2024-06-05 17:00
Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024(Globenewswire)
2024-05-15 20:00
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024(Globenewswire)
2024-05-15 00:53
SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q1 2024(Investorplace)
2024-05-14 20:00
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates(Globenewswire)
2024-05-06 20:00
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024(Globenewswire)
2024-05-05 20:00
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer(Globenewswire)
2024-04-21 20:00
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024(Globenewswire)
2024-03-27 04:01
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat(Globenewswire)
2024-03-24 19:00
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors(Globenewswire)
2024-03-24 18:15
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates(Globenewswire)
2024-02-28 19:00
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences(Globenewswire)
2024-01-25 07:58
Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock(Globenewswire)
2024-01-23 04:45
Sagimet Biosciences Announces Proposed Public OfferingÂ of Series A Common Stock(Yahoo Finance)
2024-01-22 10:10
Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH(Prnewswire)
2024-01-21 18:00
Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH(Globenewswire)
2023-12-03 19:00
Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic(Globenewswire)

Page 1 of 2

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.